secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001104659-24-122387
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio appoints David Arkowitz and António Parada as independent directors
------------------------------------------------------------------------

- David Arkowitz (Alkeus Pharma CFO) and António Parada (FairJourney Biologics CEO) join board effective Nov 25, 2024.
- Arkowitz brings financial expertise; Parada adds antibody discovery depth; CEO cites alignment with next-gen strategy.
- Departing director General Tom Hill thanked for 16 years of service; board now three Class I directors.
- Annual meeting on Nov 21 passed all proposals: elected three directors, ratified Grassi & Co., and approved say-on-pay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000110465924122387/0001104659-24-122387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000110465924122387/tm2429233d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-122387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer